会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • Hydrogen and oxygen based photoresist removal process
    • 氢和氧基光刻胶去除工艺
    • US20060281312A1
    • 2006-12-14
    • US11147959
    • 2005-06-08
    • Patricia SmithLaura MatzVinay Shah
    • Patricia SmithLaura MatzVinay Shah
    • H01L21/302H01L21/461
    • H01L21/31138G03F7/427
    • The present invention provides a photoresist removal process and a method for manufacturing an interconnect using the same. One embodiment of the photoresist removal process includes, among other steps, providing a low dielectric constant (k) substrate having a photoresist layer located thereover, and removing the photoresist layer using a plasma which incorporates a gas which includes hydrogen or deuterium and a small amount of oxygen less than about 20 volume percent of the gas. Another embodiment of the photoresist removal process includes, among other steps, providing a low dielectric constant (k) substrate having a photoresist layer located thereover, removing a bulk portion of the photoresist layer using a plasma which incorporates a gas which includes hydrogen or deuterium, and removing a small portion of the photoresist layer using a plasma which incorporates a gas which includes oxygen, wherein the order of the two removing steps is interchangeable.
    • 本发明提供一种光致抗蚀剂去除方法及其制造方法。 除了其他步骤之外,光致抗蚀剂去除方法的一个实施方案包括提供具有位于其上的光致抗蚀剂层的低介电常数(k)衬底,以及使用包含氢或氘和少量气体的等离子体去除光致抗蚀剂层 的氧气小于约20体积%的气体。 除了其他步骤之外,光致抗蚀剂去除方法的另一个实施方案包括提供具有位于其上的光致抗蚀剂层的低介电常数(k)衬底,使用包含氢或氘的气体的等离子体去除光致抗蚀剂层的主体部分, 以及使用包含氧气的等离子体去除一部分光致抗蚀剂层,其中两个除去步骤的顺序是可互换的。
    • 9. 发明授权
    • Prevention of cell migration initiation with CMV US28 receptor antagonists
    • 用CMV US28受体拮抗剂预防细胞迁移起始
    • US06420121B1
    • 2002-07-16
    • US09387044
    • 1999-08-31
    • Jay NelsonDaniel StreblowCecilia Soderberg-NauclerPatricia SmithFronziska Ruchti
    • Jay NelsonDaniel StreblowCecilia Soderberg-NauclerPatricia SmithFronziska Ruchti
    • G01N3353
    • G01N33/5061A61K31/00A61K31/395G01N33/5008G01N33/5029G01N33/566
    • There is disclosed an assay system for determining therapeutic activity for treating restenosis, atherosclerosis, chronic rejection syndrome and graft versus host disease (GVHD) by measuring inhibition of cell migration activity in smooth muscle cells expressing a US28 receptor from the CMV genome. Specifically, there is disclosed a method for measuring inhibition of cell migration in isolated cells transfected with US28 or infected with CMV and stimulated with a ligand. There is further disclosed a method for treating atherosclerosis, restenosis, chronic rejection syndrome and graft versus host disease (GVHD), comprising administering an effective amount of an agent that is a US28 receptor antagonist, wherein a US28 receptor antagonist comprises an inhibitor compound that prevents transduction of US28 receptor signal stimulated by a US28 receptor ligand, wherein a US28 receptor ligand is selected from the group consisting of RANTES, MIP-1&agr; and MCP. The invention further provides a method for treating restenosis, atherosclerosis, chronic rejection syndrome and GVHD by administering KHSV encoded vMIP-2, fractalkine or herbimycin.
    • 公开了通过测量来自CMV基因组的表达US28受体的平滑肌细胞中细胞迁移活性的抑制来确定治疗再狭窄,动脉粥样硬化,慢性排斥综合征和移植物抗宿主病(GVHD)的治疗活性的测定系统。 具体地,公开了一种测量用US28转染或用CMV感染并用配体刺激的分离的细胞中细胞迁移抑制的方法。 还公开了一种治疗动脉粥样硬化,再狭窄,慢性排斥综合征和移植物抗宿主病(GVHD)的方法,包括给予有效量的US28受体拮抗剂的试剂,其中US28受体拮抗剂包含防止 US28受体信号被US28受体配体刺激的转导,其中US28受体配体选自RANTES,MIP-1α和MCP。 本发明还提供了一种通过施用编码的VHS-2,fractalkine或者草甘膦来治疗再狭窄,动脉粥样硬化,慢性排斥综合征和GVHD的方法。